What should be checked before retaining or replacing a D5 material?
Treat this as two linked reviews: identify the exact supplied product, then assess the intended product and market against current requirements. “Contains cyclopentasiloxane” does not establish that a material is a neat carrier, and a familiar trade product does not establish that a finished cosmetic may be sold in every market.
The cyclopentasiloxane ingredient reference provides ingredient context. This article explains how to organize a review packet, not how to approve a formula or select a universal substitute.
A volatile carrier and an elastomer blend are different records
Dow describes DOWSIL SH 245 Fluid as a volatile fluid composed mainly of cyclopentasiloxane. Its technical data sheet distinguishes typical property data from sales specifications. Dow's specialty-elastomer literature also includes Cyclopentasiloxane (and) Dimethicone Crosspolymer blends. A blend containing a polymer is not interchangeable with the carrier alone merely because both names include D5. See the SH 245 technical data sheet and Dow specialty-elastomer guide.
Sources reviewed November 10, 2026. Obtain current composition, specifications, handling and lot information for the actual grade. The distinction above is not a claim about purity, interchangeability or fitness for a particular finished product.
Read the EU dates with their scope
Commission Regulation (EU) 2024/1328, adopted May 16, 2024, replaces REACH Annex XVII entry 70. Its concentration threshold is equal to or greater than 0.1% by weight of each respective D4, D5 or D6 substance. D4/D5 wash-off cosmetics have the earlier date after January 31, 2020. For other cosmetics, including leave-on products, the stated later date is after June 6, 2027. The general June 6, 2026 date is not a universal cosmetic deadline. Other derogations are not blanket permission. Check the official regulation and annex and ECHA cyclosiloxanes information.
Regulatory sources reviewed November 10, 2026. Ask a qualified reviewer to determine applicability, current amendments and other requirements for the actual product, market and placing-on-the-market activity. This brief source summary is not legal advice or finished-product approval.
A fictional review packet with two missing answers
A team reviewing Project D-07 has a purchasing spreadsheet that says “D5 silicone” and a brief that says “EU launch.” There is no trade name, supplied composition, product category or launch date. A second attachment refers to an elastomer gel. No one has established whether the two records describe the same material.
The correct starting point is to resolve identity and scope. Do not calculate a finished-product D5 content from the ingredient nickname. Do not assign a market decision from a calendar date alone. The ingredient investigation worksheet provides space for both source facts and unanswered questions.
| Review area | Fictional evidence available | What is missing |
|---|---|---|
| Supplied material | Spreadsheet says “D5 silicone” | Exact trade grade, supplier and current composition |
| Blend identity | Separate file mentions an elastomer gel | Whether this is the purchased material and which components it contains |
| Intended product | Project D-07 brief | Product type, use context and relevant exposure information |
| Market | “EU launch” | Activity, timing and qualified applicability review |
| Development | A substitution is proposed | Defined performance goals and an authorized comparison plan |
A reviewer can return this packet for clarification without declaring the material universally allowed or banned. The missing facts are the work to complete.
Preserve the original while investigating alternatives
If an alternative is being considered, define what must be evaluated: supplied identity, process behavior, package interaction, sensory goals and relevant studies. A change in carrier or blend can require revisiting more than a single ingredient line. Keep the original material and prototype version identifiable while documenting the proposed change.
Record each study as planned, underway or supported by actual results. Avoid “equivalent” until its narrow meaning and evidence are stated. Sensory similarity does not establish identical composition, safety, preservation or regulatory status. The appropriate reviewers must define and assess those questions separately.
Close the packet with an evidence list, open items, owners and a dated decision scope. For formulation software evaluation, request an export that preserves grade identity, component evidence, market-review dates and unresolved tasks. Observing that record is useful; it is not certification that the software's regulatory catalogue is complete or that the product is approved for sale.
Keep the research beside the formula.
Build formulas, trace ingredient decisions, watch costs, and carry the right records into production. Free account first · no card. Pro trial: card required · $0 today · then $49/month unless canceled before the first charge.